ALT vs AMLX: fair value comparison
Altimmune, Inc. and Amylyx Pharmaceuticals, Inc. · Updated 2026-10-19
ALT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. AMLX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ALT currently ranks higher by quality score.
| ALT | AMLX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $2.20 | $26.34 |
| 12-month range | $2.20–$6.18 | $11.38–$39.66 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #217 of 301 Healthcare | #218 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | Declining |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: ALT fair value analysis · AMLX fair value analysis